INTRODUCTION
============

Myelodysplastic syndrome (MDS) is a group of malignant clonal diseases originating from hematopoietic stem cells and characterized by pathophysiological changes in dysplasia and ineffective hematopoiesis of clonal hematopoietic stem cells. Its clinical manifestations include cytopenia of one or more lineages, dysplasia of cells in bone marrow and peripheral blood, and an obvious tendency to transform into acute leukemia, particularly in more advanced forms of MDS.[@B1][@B2][@B3][@B4] The overall survival (OS) and risk of leukemic transformation in such patients are highly variable.[@B5][@B6][@B7][@B8][@B9] The International Prognostic Scoring System (IPSS) has widely been used as the golden prognostic classification with primary MDS.[@B10]

Recently, the newer prognostic system Revised IPSS (IPSS-R) was proposed.[@B8] Both systems indicate that cytogenetics is an independent prognostic factor of MDS concerning OS and acute myeloid leukemia (AML) transformation.[@B9][@B10]

Trisomy 8 (tr8 or +8) is the most common chromosomal gain in MDS, which is present in 5% of all MDS patients in Western countries.[@B11] However, it accounts for about 30--35% in Chinese patients with abnormal karyotype and represents 14--20% of MDS patients in Western countries.[@B12][@B13][@B14] Although tr8 as sole anomaly is categorized as intermediate IPSS cytogenetic subgroup, the outcome varies greatly both in terms of OS and risk of evolution to AML.[@B5][@B15][@B16] Furthermore, patients with trisomy 8 are more likely to improve hematologically with immunosuppressive treatment (IST) compared with patients with other forms of MDS.[@B17] Recently, the optimal therapies for the trisomy 8 patients have been investigated.[@B18] Thus, the analysis of further prognostic parameters for OS and AML transformation in large series of MDS patients with trisomy 8 is of importance. There are few studies that have systematically analyzed the clinical prognostic factors of primary MDS with tr8 in Chinese patients.[@B12][@B13][@B15] In this study, we aimed to assess clinical features and identify prognostic factors in Chinese primary MDS with tr8 anomaly, and compare the prognostic value of IPSS and IPSS-R in this group by our single institution cohort.

MATERIALS AND METHODS
=====================

Patients
--------

We retrospectively analyzed 86 (23%) patients with MDS from a series of 374 cases diagnosed and followed up in our institution between July 2002 and March 2013. A total of 86 cases diagnosed with MDS with isolated tr8 or with tr8 and other additional cytogenetic aberrations were enrolled for the study. The diagnosis of the patients were reviewed, and reclassified according to World Health Organization (WHO) classification of 2008,[@B16] and the exact date of diagnosis with bone marrow examination and cytogenetic assessment had to be documented. Exact WHO type, medullary blast count, differential count, bl-ood cell counts, karyotype, and transfusion requirement were documented. Transfusion dependency means that at least 4 units of red blood cell (RBC) transfusions had to be administered within 8 weeks, which was defined as described by Malcovati, et al.[@B19] As a result, 86 patients had met the criteria and were enrolled. The studies had been approved by ethics committees of participating institutions and conducted in accordance with the Declaration of Helsinki. All participants had given informed consent.

Cytogenetics
------------

All the bone marrow chromosome studies were performed by following chromosome-banding procedures, and at least 20 metaphases were analyzed. Abnormal clones were described in accordance with the 2006 International System for Human Cytogenetic Nomenclature (ISCN),[@B20] and aberrations were counted following the International Working Group on MDS Cytogenetics (IWGMC) consensus guidelines.[@B21] Fluorescence *in situ* hybridization (FISH) analysis was performed on short-term cultured bone marrow. Sample preparations and hybridizations using commercially available probes were performed according to manufacturer\'s recommendations (Vysis, Downers Grove, IL, USA). Systematic screening for del(5q), del(7q)/-7, +8, del(20q), and -Y was performed on each case. A minimum of 500 interphase cells were analyzed. If the cells with abnormal signal were less than 5%, 1000 inter-phase cells were screened. Normal control values were previously established by using five normal samples of bone marrow donors and 15 bone marrow samples of iron deficiency anemia patients with normal karyotype. Using the method of x±258 standard deviations (99% confidence interval), the cut-off level for normal range values was established for each probe as follows: del (5q)\<0.5%; del(7q)/-7\<0.2%; +8\<0.5%; del(20q)\<1%; and -Y\<5%.

Long-term clinical follow-up
----------------------------

According to WHO classification, all patients were administered with supportive care. Patients were followed up with repeated examinations, including bone marrow aspirate, cytogenetics and molecular genetics, every 6 months or whenever any change in their clinical condition occurred. Follow-up was completed by the end of March 2013.

Statistical analysis
--------------------

For the analysis of survival and AML development, patients who were still alive were censored at the date of last observation. Survival time was counted from diagnosis. OS was defined as the time from diagnosis to death or date of last follow-up. The time to AML transformation was defined as time to bone marrow blast increase to 20%, according to the WHO classification.[@B22] OS was analyzed with the Kaplan-Meier method and followed by the log-rank.[@B23] All univariate tests were two tailed and *p* value ≤0.05 was considered as significant. Finally, Cox proportional hazards multivariate model was used to define the OS and to assess the relevant prognostic variables.[@B24] For multivariate analysis, a *p* value ≤0.05 was considered significant. All analyses were performed using SPSS software (version 18.0; SPSS Inc., Chicago, IL, USA).

RESULTS
=======

Patients\' hematological characteristics
----------------------------------------

The 86 patients with trisomy 8 abnormality were analyzed as a whole. Fifty-four patients were male (62.8%) and 32 were female (37.2%), with median age of 48.5 years (range of 21--79). The median hemoglobin level, absolute neutrophil count (ANC) and platelet count were 76.5 g/L (range of 42--134), 1.5×10^9^/L (range of 0.08--10.1), and 64.5×10^9^/L (range of 7--297), respectively. The median proportion of bone marrow blasts was 3% (range of 0--18) ([Table 1](#T1){ref-type="table"}). According to the IPSS, therefore, 76.8% had hemoglobin level \<100 g/L, 54.7% had ANC \<1.8×10^9^/L and 55.8% had a platelet count \<100×10^9^/L. At the time of diagnosis, 35% patients regularly needed RBC transfusion. In total, 49 (57.0%) patients had a single trisomy 8 abnormality, while 19 (22.1%) had one additional aberration and 18 (20.9%) had more than three aberrations (complex karyotype including tr8). According to the 2008 WHO classification, the patients were classified as 19 cases of RCUD, 1 case of RARS, 25 cases of RCMD, 15 cases of RAEB1, 20 cases of RAEB2, and 6 cases of MDS-U.

OS
--

The median follow-up time was 22 months. The median OS for our study group was 23.0 months. Univariate analysis by log-rank test was done to screen the parameters potentially associated with the time of survival ([Table 1](#T1){ref-type="table"}). Age above 60 years old, marrow blasts, cytogenetic complexity, ANC, platelet count (\<50×10^9^/L) and transfusion dependency at diagnosis were associated with a worse prognosis. Then, we further assessed the WHO Classification-Based Scoring System (WPSS) for the OS, and found that the intermediate group vs. high and very high group has significant difference ([Fig. 1](#F1){ref-type="fig"}). In the multivariate analysis, age, marrow blasts, cytogenetic status and the need of RBC transfusion at diagnosis were independent parameters for the time of survival ([Table 2](#T2){ref-type="table"}). For the cytogenetic status, we found a difference in the time of survival between the karyotype complexity groups: the median time for the groups (tr8, tr8+1, and tr8+≥2) was 32.3, 22.5, and 11.9 months, respectively, with the difference being statistically significant between tr8 and tr8+1 or tr8+≥2 (*p*\<0.05) or between tr8+1 and tr8+≥2 (*p*\<0.05) ([Fig. 2](#F2){ref-type="fig"}).

It was found that both IPSS and IPSS-R could successfully predict the OS (*p*\<0.05), however, the IPSS has the advantage for predicting the AML transformation risk (*p*\<0.05) than the IPSS-R (*p*=0.154). In the IPSS groups, there was no significant difference in the OS between intermediate-2 risk group and high risk groups (*p*=0.535) ([Fig. 3](#F3){ref-type="fig"}). When the prognosis risk scores were recalculated according to the IPSS-R; 37.5% (18 cases) intermediate-1 from the IPSS group was redistributed into the IPSS-R low-risk group, 18.8% (9 cases) was into high-risk group; 48% (13 cases) intermediate-2 from the IPSS was put into the IPSS-R high-risk group, 30% (8 cases) intermediate-2 was put into very high-risk group, and 81.8% (9 cases)

AML transformation
------------------

During the entire follow time, there were 37 (43%) of the 86 patients progressed to AML. Then, we explored the influence of parameters on the risk of AML progression by univariate analysis, and found that cytogenetic status and marrow blasts \>5% were significantly (*p*\<0.05) associated with the increased risk of the AML transformation. In the multivariate analysis, the cytogenetic complexity and the count of bone marrow blasts were identified to be the independent risk factors for AML evolution ([Table 3](#T3){ref-type="table"}).

DISCUSSION
==========

MDS is characterized by highly clinical heterogeneous behavior, and numerous studies have suggested that the Asian MDS patients are different from those in Western countries.[@B25][@B26][@B27][@B28] The median age in our cohort was younger (48.5 years old) than the reported cases in the Western countries (72 years old). The incidence of the MDS with the tr8 abnormality is different between the Western and the Asian. In China, trisomy 8 is the most frequent karyotypic abnormality.[@B13][@B14][@B29][@B30][@B31] Furthermore, the clinical characteristic and prognostic factors of Asian MDS patients are different from Western patients.[@B26][@B32] Therefore, we considered that the prognostic parameters of this group may be different between the Westerners and Chinese.

As for the significance of clinical parameters for the OS and AML development in the present study, age, low platelet, and degree of ANC had an impact on OS but not on AML transformation. The significantly bad prognosis of low platelet count had been described in MDS patients.[@B31] However, hemoglobin level had no significance (*p*\>0.05) for OS. Transfusion dependency, a confounding factor, could reflect the more objective parameter of severity of anemia and had impact on the survival (*p*\<0.05), but not on the AML evolution. In the MDS patients a small scale of study showed that red cells transfusion at diagnosis and the intensity may be an important independent prognostic factor.[@B33] In most Chinese patients, the transfusion threshold for RBC was lower than 60 g/L, and the patients with Hb concentrations greater than 70 g/L had no symptoms related to anemia and did not require red cell transfusion. On the other hand, the threshold for RBC transfusion in the westerns countries is lower than 80 g/L. Therefore, the prognostic value of concentration threshold of 80 g/L may possibly explain the difference of the Hb for the prognosis of survival. We further assessed the WPSS for OS, and found that high and very high groups had significance for OS (*p*\<0.001). This finding needs to be confirmed by more studies. In the present study, multivariate analysis showed that the patient with marrow blasts ≥5% combining the trisomy 8 abnormalities had poorer prognosis on OS (*p*\<0.05) and AML evolution (*p*\<0.05) than the patient with \<5% marrow blasts, in accordance with the findings by Saumell, et al.[@B34]

The new proposals for cytogenetic categorization, like the previous IPSS classification, have regarded isolated trisomy 8 as an intermediate risk prognosis to MDS. The median OS reported for patients with single trisomy 8 ranged between 11 and 25 months, and for the patients in the intermediate IPSS subgroup between 23 and 32 months.[@B5][@B6][@B10][@B35] Our results are in accordance with the results reported by Saumell, et al.;[@B34] in our study the median OS for patients with single trisomy 8 was 32.3 months. We found that the complexity of additional aberrations had impact on OS; the single tr8 between tr8+1 aberration (*p*=0.003), tr8+1 aberration between tr8+≥2 aberrations (*p*=0.001), and the median OS for tr8+1 and tr8+≥2 were 22.5 and 11.9 months respectively. This phenomenon was different from the results by Haase, et al.,[@B35] who showed that tr8 plus one additional anomaly had a better prognosis and were classified into good-prognostic cytogenetic subgroup. However, our data demonstrated that there was statistical difference in median survival between the two subgroups. Similarly, the progression to AML risk increased with the complexity of the cytogenetic abnormalities, but the result must be confirmed with multicenter studies.

Compared with the IPSS, IPSS-R defined 16 specific abnormalities better, grouped into five different risk groups, and classified a number of uncommon cytogenetic subsets in accordance with its sophisticated stratification.[@B9] In addition, recent evidence suggests that the prognostic significance of poor cytogenetics has been underestimated in the IPSS, while the defect has been improved in the IPSS-R prognostic models.[@B36] We applied the IPSS-R to an independent group of 86 Chinese MDS patients with tr8 alterations, and evaluated the predictive power of the two systems for the OS and the risk of AML transformation. Two systems both could successfully discriminate risk groups for survival. The same cohort of patient distribution into risk groups varied according to the scoring systems: IPSS-R was more specific than IPSS for discriminating survival risk groups, but had no advantage in the prognosis for the risk of the AML transformation in this cohort. This result can be explained by the limits of the small number of enrolled patients, and need to be confirmed by more multicenter researches.

In summary, the results of this retrospective study confirmed the impact of the number of additional aberration on MDS patients with tr8, and first assessed the importance of clinical parameters for the outcomes. This series may be useful for the design of more clinical trials in Chinese MDS patients with tr8.
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###### Univariate Analysis of Prognostic Parameters for OS and AML Progression
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  Parameters               n (%)       OS                  Progress to AML (cumulative probability of AML transformation at 2 yrs)   *p* value   
  ------------------------ ----------- ------------------- ------------------------------------------------------------------------- ----------- ---------
  Sex                                                      0.643                                                                                 0.281
   Female                  32 (37.2)   22.5 (0.7--67)                                                                                37.5%       
   Male                    54 (62.8)   23 (1.2--63)                                                                                  46.3%       
  Age                                                      0.012                                                                                 0.581
   ≤60 yrs                 66 (76.8)   23.2 (0.7--67)                                                                                30.8%       
   \>60 yrs                20 (23.2)   22.5 (1.8--40.5)                                                                              47.6%       
  Hemoglobin, g/dL                                         0.128                                                                                 0.483
   \<8                     47 (54.7)   18.6 (7.6--61)                                                                                42.6%       
   8--10                   19 (22.1)   25.9 (5.9--63)                                                                                21.1%       
   \>10                    30 (23.2)   28.6 (0.7--40.4)                                                                              40.0%       
  ANC, ×10^9^/L                                            0.022                                                                                 0.904
   \>1.8                   37 (43.0)   28.6 (0.7--67)                                                                                18.9%       
   0.8--1.8                19 (22.1)   22 (7.6--39)                                                                                  63.2%       
   \<0.8                   30 (34.9)   18.6 (1.2--61)                                                                                40.0%       
  Platelets, ×10^9^/L                                      0.020                                                                                 0.607
   \<50                    33 (38.4)   17 (0.7--61)                                                                                  33.3%       
   50--100                 32 (37.2)   22.5 (7.6--39)                                                                                37.5%       
   \>100                   21 (24.4)   37 (1.2--67)                                                                                  28.6%       
  BM-blast (%)                                             \<0.001                                                                               \<0.001
   0--2                    40 (46.6)   38 (14--67)                                                                                   10.0%       
   \>2--\<5                10 (11.6)   24.5 (12.3--52.5)                                                                             20.0%       
   5--10                   25 (23.2)   13.5 (6.2--28.9)                                                                              76.0%       
   \>10--20                11 (18.6)   7.6 (0.7--21)                                                                                 63.6%       
  WHO 2008 subtypes                                        0.001                                                                                 \<0.001
   RCUD/RARS               20 (23.2)   38.0 (18.5--63)                                                                               5.0%        
   RCMD/RCMD-RS            25 (29.1)   26.6 (12.3--67)                                                                               20.0%       
   RAEB-1                  15 (17.4)   11.9 (6.5--28.6)                                                                              93.3%       
   RAEB-2                  20 (23.2)   13.9 (0.7--22.5)                                                                              55.0%       
   MDS-U                   6 (7.1)     39.0 (14--46.8)                                                                               0           
  Transfusion dependence                                   0.009                                                                                 0.180
   Yes                     30 (34.9)   18.4 (1.2--63)                                                                                            
   No                      56 (65.1)   25.9 (0.7--67)                                                                                32.1%       
  Cytogenetic status                                       \<0.001                                                                   46.7%       0.021
   Tr8 single              49 (57.0)   32.3 (1.2--67)                                                                                26.5%       
   Tr8+1                   19 (22.1)   22.5 (1.8--43)                                                                                26.3%       
   Tr8+≥2                  18 (20.9)   11.9 (0.7--24.5)                                                                              72.2%       
  IPSS risk group                                          \<0.001                                                                               0.010
   Low                     0                                                                                                                     
   Intermediate-1          48 (55.8)   36.5 (13--67)                                                                                 12.5%       
   Intermediate-2          27 (31.4)   13.5 (6.2--26.6)                                                                              70.4%       
   High                    11 (12.8)   8.8 (0.7--21)                                                                                 54.5%       
  IPSS-R risk group                                        \<0.001                                                                               0.154
   Very low                0           \-                                                                                            \-          
   Low                     18 (20)     39.0 (23--67)                                                                                 11.1%       
   Intermediate            27 (31.4)   26.6 (12.4--63)                                                                               22.2%       
   High                    24 (27.9)   16.7 (7.6--40.7)                                                                              45.8%       
   Very high               17 (19.7)   10.4 (0.7--21)                                                                                76.5%       
  WPSS risk group                                          \<0.001                                                                               0.106
   Very low                0           \-                                                                                            \-          
   Low                     0           \-                                                                                            \-          
   Intermediate            34 (39.5)   38.9 (13.9--67)                                                                               8.8%        
   High                    28 (32.6)   16.7 (5.9--36.5)                                                                              32.1%       
   Very high               24 (27.9)   12.3 (0.7--28.6)                                                                              41.7%       

ANC, absolute neutrophil count; WHO, World Health Organization; RCUD, refractory cytopenia with unlineage dysplasia; RCMD, refractory cytopenia with multilineage dysplasia; RARS, refractory anemia with ring sideroblasts; RAEB, refractory anemia with excess blasts; MDS-U, myelodysplastic syndromes unclassifiable; tr8, +8, trisomy 8; IPSS, International Prognostic Scoring System; IPSS-R, Revised IPSS; WPSS, WHO Classification-Based Scoring System; OS, overall survival; AML, acute myeloid leukemia; BM, bone marrow.

###### Cox Model for OS
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                                            Coefficient   Expo (coefficient)   95% CI       *p* value
  ----------------------------------------- ------------- -------------------- ------------ -----------
  Age                                       -0.810        0.445                0.80--0.25   0.007
  ANC                                       0.237         1.267                1.70--0.95   0.111
  Thrombocytopenia                          -0.026        0.974                1.39--0.68   0.885
  BM-blasts                                 0.995         2.704                3.62--2.02   \<0.001
  Transfusion dependency                    0.666         1.947                3.51--1.08   0.026
  Cytogenetics (tr8+1 and tr8+≥2 vs. tr8)   1.233         3.43                 5.95--1.98   \<0.001

ANC, absolute neutrophil count; CI, confidence interval; BM, bone marrow; OS, overall survival.

###### Cox Model for AML Progression
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                                           Coefficient   Expo (coefficient)   95% CI       *p* value
  ---------------------------------------- ------------- -------------------- ------------ -----------
  BM-blasts                                1.060         2.886                6.18--1.92   \<0.001
  Cytogenetics (tr8+1and tr8+≥2 vs. tr8)   1.128         3.091                6.64--1.44   0.004

AML, acute myeloid leukemia; CI, confidence interval; tr8, +8, trisomy 8; BM, bone marrow.
